Overview

This information brief explains the Medical Cannabis Therapeutic Research Act, Minnesota Statutes, sections 152.22 to 152.37, enacted in 2014 and amended through the 2019 first special session. The act established a patient registry program that allows qualifying patients to use and possess cannabis for medical purposes. A brief history of medical cannabis legislation in Minnesota is also provided, including changes to qualifying medical conditions and delivery methods.

Contents

Overview of the Law ................................................................. 2
General Design of the Registry Program ........................................ 4
The Patient Registry Program ...................................................... 5
   MDH Program Administration ................................................... 5
   Patients .................................................................................. 8
Manufacturers ........................................................................... 13
Health Care Practitioners .......................................................... 19
Operation of the Program ........................................................... 23
Legislative History of Medical Cannabis Regulation in Minnesota .......... 26
Changes to Qualifying Medical Conditions and Delivery Methods .......... 29

Please note: The House Research Department provides services to the Minnesota House of Representatives; it does not and cannot represent or provide legal services to private individuals, private entities, or other government organizations. This publication is not intended to provide legal advice and should not be used as a substitute for consulting with a private attorney. Serious criminal and civil consequences can follow a possession or distribution of cannabis charge. If readers have any concerns about consequences resulting from the possession or distribution of medical cannabis, they should consult a private attorney.
Overview of the Law

The Medical Cannabis Therapeutic Research Act was enacted in May 2014.¹ The law established a patient registry program, administered by the Minnesota Department of Health (MDH), which allows qualifying patients to possess and use cannabis for medical use.

The law allows two manufacturers to be registered in the state. Each manufacturer must have one manufacturing facility and eight distribution sites throughout the state.

The manufacturers may only distribute medical cannabis in pill, liquid, or topical form, and patients may only possess medical cannabis in those forms.

Qualifying medical conditions include:

1) Cancer*
2) Glaucoma
3) HIV/AIDS
4) Tourette’s syndrome
5) Amyotrophic lateral sclerosis (ALS)
6) Seizures
7) Severe and persistent muscle spasms
8) Inflammatory bowel disease, including Crohn’s disease
9) Terminal illness with life expectancy of under one year*
10) Intractable pain
11) Post-traumatic stress disorder
12) Autism spectrum disorder
13) Obstructive sleep apnea
14) Alzheimer’s disease
15) Any other condition or its treatment approved by the commissioner (subject to legislative oversight)

* Illness or treatment must produce one or more of the following: (1) severe or chronic pain; (2) nausea or severe vomiting; or (3) cachexia or severe wasting.

In December 2019, the Commissioner of Health added chronic pain and age-related macular degeneration as qualifying medical conditions, and added water-soluble cannabinoid multi-particulates and orally dissolvable products as new delivery methods. Patients with chronic pain or age-related macular degeneration will be eligible to enroll in the program beginning July 1, 2020, and will be able to obtain medical cannabis beginning August 1, 2020.

The general design of the registry program is as follows:

---

¹ Laws 2014, ch. 311; codified as Minn. Stat. §§ 152.22 to 152.37.
Minnesota's Medical Cannabis Therapeutic Research Act

General Design of the Registry Program

Patient diagnosed with qualifying medical condition

Patient sends annual application to MDH

MDH issues registry verification to patient, health care practitioner, and manufacturer

Health care practitioner continues treatment of patient for qualifying condition

Patient obtains medical cannabis

Manufacturer distributes medical cannabis to patient

Practitioner and manufacturer report to MDH

MDH submits research report to legislature and major scientific journals
General Design of the Registry Program

The general design of the registry program is explained briefly below, but many aspects are more fully detailed in subsequent sections of this publication.

Patient diagnosed with qualifying medical condition

Prior to applying to participate in the registry program, a patient must be diagnosed by a health care practitioner with one or more qualifying medical conditions.

Patient sends annual application to MDH

Once the patient receives certification of a diagnosis with a qualifying medical condition from a health care practitioner, the patient must apply to the Minnesota Department of Health (MDH) to be a part of the registry program. The patient must submit this application, along with an application fee, on an annual basis.

MDH issues a registry verification to patient, health care practitioner, and manufacturer

Once the patient has been accepted into the registry program, MDH issues a registry verification listing the patient’s information, along with the information of the patient’s registered designated caregiver or parent, legal guardian, or spouse, if applicable. The registry verification is issued to the patient, the patient’s listed health care practitioner, and the manufacturer as proof of the patient’s participation in the registry program.

Health care practitioner continues treatment of qualifying medical condition

As part of the health care practitioner’s duties, the practitioner must continue to treat the qualifying medical condition of the patient.

Manufacturer distributes medical cannabis to patient

A manufacturer may only distribute medical cannabis to a person listed on the patient’s registry verification. Final approval for distribution must be made by a licensed pharmacist after a consultation with the patient.

Patient obtains medical cannabis from manufacturer

A patient may only obtain medical cannabis from a registered manufacturer. If a patient has a registered designated caregiver or parent, legal guardian, or spouse listed on the registry verification, that person may also obtain the medical cannabis from the manufacturer on the patient’s behalf.
Reports to MDH

The health care practitioner is required to report the patient’s health records to MDH through the registry program. The manufacturer is also required to submit a report to MDH containing various information.

MDH submits reports to legislature and major medical journals

MDH is required to conduct research on the information in the registry program and submit reports to certain legislative committees as well as major medical journals.

The Patient Registry Program

MDH Program Administration

MDH and its commissioner are responsible for administering the patient registry program. The Office of Medical Cannabis within MDH administers the program. MDH functions include maintaining the patient registry and issuing registry verifications to enrolled patients, registering and regulating medical cannabis manufacturers, adding qualifying medical conditions and allowable forms of medical cannabis, providing information to health care practitioners, and adopting rules to implement the program.

Registration

Initial registration and reregistration

On December 1, 2014, MDH registered two medical cannabis manufacturers: LeafLine Labs and Minnesota Medical Solutions. Manufacturers are subject to re-registration every two years. As a condition of initial registration, each manufacturer agreed to begin distribution of medical cannabis to patients by July 1, 2015, and comply with other requirements under the law.

MDH is required to consider the following factors when determining which manufacturers to register or reregister:

- Technical expertise in cultivating medical cannabis and converting it into allowable forms
- The qualifications of the manufacturer’s employees
- The long-term financial stability of the manufacturer
- The ability to provide appropriate security measures on the premises of the manufacturer
- Whether the manufacturer has demonstrated an ability to meet the medical cannabis production needs required by the registry program
- The manufacturer’s projection and ongoing assessment of patient fees

---

2 Minn. Stat. § 152.25, subd. 1.
The commissioner may accept additional applications for registration if one of the registered manufacturers ceases to be registered. A registration agreement between the commissioner and a manufacturer is not transferrable.

**Enforcement actions against manufacturer registrations**

The commissioner has authority to revoke or not renew a manufacturer’s registration. In particular, the commissioner is authorized to not renew a manufacturer’s registration if certain individuals affiliated with the manufacturer intentionally divert medical cannabis to a person other than allowed by law. Before revoking or not renewing a registration, the commissioner must provide written notice to the affected manufacturer, and the manufacturer may request a contested case hearing. In addition, the commissioner may temporarily suspend a manufacturer’s registration for up to 90 days in certain circumstances. If the commissioner takes any enforcement action against a manufacturer that affects the ability of patients, designated caregivers, and parents and legal guardians to obtain medical cannabis from that manufacturer, the commissioner must give notice of the enforcement action and alternatives for obtaining medical cannabis to affected patients, designated caregivers, and parents, legal guardians, and spouses.

**Ongoing enforcement**

In addition to taking enforcement action against manufacturer registrations, the commissioner may use the tools and authority in the Health Enforcement Consolidation Act (Minnesota Statutes, sections 144.99 to 144.993) to enforce medical cannabis statutes.

**Financial audit and examination**

MDH may inspect the manufacturer’s financial documents through an examination of its annual certified financial audit or through an examination of its business affairs. (For more on manufacturer financial audits, see page 15).

**Adding additional allowable forms and qualifying medical conditions**

The commissioner may add to the list of qualifying medical conditions and also add to the list of allowable forms of medical cannabis. The commissioner is prohibited, however, from adding smoking as an allowable form. To add an additional form or condition, the commissioner must evaluate petitions received and must add the form or condition if the commissioner determines that the addition is warranted based on evidence and research. The commissioner must then notify the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services as to the reasons for the addition. This notice must include any

---

3 Minn. Stat. § 152.25, subds. 1, 1a, 1b, 1c  
4 Minn. Stat. § 144.99, subd. 1.  
5 Minn. Stat. § 152.37.  
6 Minn. Stat. § 152.27, subd. 2, para. (b).
public comments the commissioner has received and any guidance the commissioner has received from the Task Force on Medical Cannabis Therapeutic Research. The notification must be given by January 15 of the year the commissioner wishes to make the change. The change becomes effective August 1 of that year unless the legislature provides otherwise by law.

**Rulemaking authority**

MDH adopted the initial medical cannabis rules using the expedited rulemaking process under Minnesota Statutes, section 14.389. MDH was required to have in place rules necessary for the manufacturers to begin distributing medical cannabis to patients by July 1, 2015. The initial rules were adopted January 20, 2015, and are found in Minnesota Rules, chapter 4770. MDH must use the standard rulemaking process for any subsequent rulemaking.

**Reports**

The commissioner is required to regularly update the Task Force on Medical Cannabis Therapeutic Research and the chairs and ranking minority members of certain legislative committees regarding any changes in federal law or regulation of medical cannabis or hemp, and market demand and supply in Minnesota for products made from hemp that can be used for medicinal purposes. The commissioner may also submit medical research collected through the registry program to federal agencies with regulatory authority over medical cannabis in order to demonstrate the effectiveness of medical cannabis for treating qualifying medical conditions. The commissioner must also submit findings from the registry program to both the legislature and major scientific journals.

**Range of compounds**

MDH must annually review existing medical and scientific literature on the recommended range of dosages and chemical compounds for each qualifying medical condition and must publicly report that review. The most recent review was published in May 2019 and is posted on the MDH website.

**Adverse incidents**

MDH adopted rules to require law enforcement and emergency medical personnel to report incidents when individuals not authorized to use medical cannabis are found in possession of medical cannabis. The department also adopted rules requiring law enforcement, health care professionals, registered patients, caregivers, and manufacturers to report serious adverse

---

7 Minn. Stat. §§ 152.26; 152.261.
8 Minn. Stat. § 152.25, subd. 4.
9 Minn. Stat. § 152.25, subd. 2.
11 Minn. Stat. § 152.261; Minn. Rules, parts 4770.4004 and 4770.4010.
incidents involving medical cannabis, including incidents involving an overdose of medical cannabis.

Patients

Participation in the registry program

To participate in the registry program, a patient must first consult with a health care practitioner to determine whether the patient has one or more qualifying medical conditions. The following conditions are qualifying medical conditions:\n
1) Cancer*
2) Glaucoma
3) HIV/AIDS
4) Tourette’s syndrome
5) Amyotrophic lateral sclerosis (ALS)
6) Seizures
7) Severe and persistent muscle spasms
8) Inflammatory bowel disease, including Crohn’s disease
9) Terminal illness with life expectancy of under one year*
10) Intractable pain
11) Post-traumatic stress disorder
12) Autism spectrum disorder
13) Obstructive sleep apnea
14) Alzheimer’s disease
15) Any other condition or its treatment approved by the commissioner (subject to legislative oversight)

* Illness or treatment must produce one or more of the following: (1) severe or chronic pain; (2) nausea or severe vomiting; or (3) cachexia or severe wasting.

Laws 2014, chapter 311, section 20, required the Commissioner of Health to consider adding intractable pain to the list of qualifying medical conditions before considering adding any other condition to the list. The commissioner added intractable pain\(^{13}\) to the list of qualifying medical conditions using the procedure in Minnesota Statutes, section 152.27, subdivision 2, paragraph (b). Patients with intractable pain were eligible to enroll in the registry program beginning July 1, 2016, and to receive medical cannabis beginning August 1, 2016. In the following years, the

\(^{12}\) Minn. Stat. § 152.22, subd. 14; additional conditions added by Commissioner of Health.

\(^{13}\) Intractable pain is defined in Minnesota Statutes, section 152.125, subdivision 1, as a pain state in which the cause of the pain cannot be removed or otherwise treated with the consent of the patient and in which, in the generally accepted course of medical practice, no relief or cure of the cause or pain is possible, or none has been found after reasonable efforts. According to MDH, intractable pain is a subset of chronic pain.
commissioner added post-traumatic stress disorder, autism spectrum disorder, obstructive sleep apnea, and Alzheimer’s disease to the list of qualifying medical conditions.

In December 2019, the Commissioner of Health added chronic pain\(^\text{14}\) and age-related macular degeneration as qualifying medical conditions. Patients with chronic pain or age-related macular degeneration will be eligible to enroll in the program beginning July 1, 2020, and will be able to obtain medical cannabis beginning August 1, 2020.

Following diagnosis of a qualifying medical condition, the patient must submit an application and application fee to MDH to enroll in the registry program.\(^\text{15}\) The application must include a health care practitioner’s certification of diagnosis and other forms required by MDH. The application must also include the name, mailing address, and date of birth of the patient, the designated caregiver if the patient requires assistance with administering or obtaining medication, and the patient’s parent, legal guardian, or spouse if that individual will act as caregiver.

As part of the yearly application, the patient must pay an application fee of $200. If the patient attests to receiving Social Security disability or Supplemental Security Insurance payments, or to being enrolled in Medical Assistance or MinnesotaCare, the patient’s yearly fee is $50.\(^\text{16}\)

The commissioner must approve or deny an application within 30 days of receiving the application and fee. Once the application is approved by MDH, the patient receives a registry verification.

**Reasons to deny participation in the registry program\(^\text{17}\)**

The commissioner is authorized to deny a patient entry into the registry program only if the patient:

- does not have a certification from a health care practitioner of a diagnosis with a qualifying medical condition;
- does not provide the required information or signed disclosures;
- has previously been removed from the registry program for a violation of patient duties or the commission of a crime related to medical cannabis; or
- provides false information.

---

\(^{14}\) According to a September 2019 Department of Health issue brief on adding chronic pain as a qualifying medical condition, chronic pain does not have a single definition. The term has been defined as pain that persists beyond the normal time of healing (which may be one month, three months, or six months), or pain that occurs at least half of the days for six months or more. Chronic pain also may trigger central sensitization, which is a prolonged increase in the excitability and firing of neurons in the central nervous system.

\(^{15}\) Minn. Stat. § 152.27, subd. 3.

\(^{16}\) Minn. Stat. § 152.35.

\(^{17}\) Minn. Stat. § 152.27, subd. 6.
If a patient is denied entry, the commissioner must give the patient a written reason for the denial. A denial is considered a final decision of the commissioner and is subject to judicial review under the Administrative Procedure Act, pursuant to chapter 14.

**Responsibilities during participation**  

To maintain enrollment in the registry program, the patient must resubmit a copy of the certification of diagnosis to MDH on a yearly basis and pay a yearly application fee. Patients must also continue to receive regularly scheduled treatment for that qualifying medical condition and report changes in that condition to their health care practitioner throughout enrollment in the registry program.

**Registered designated caregivers**  

A patient is permitted to have a registered designated caregiver if the patient’s health care practitioner certifies that the patient has a developmental or physical disability that means the patient needs assistance in administering the medication or acquiring the medication from a distribution facility. The registered designated caregiver must agree, in writing, to act as the patient’s caregiver. As conditions of registration, the caregiver must:

- be at least 18 years of age;
- agree to only possess the patient’s medical cannabis for purposes of assisting the patient; and
- agree to not be a caregiver for more than one patient, unless the patients reside in the same residence.

A registered designated caregiver may also be enrolled in the registry program as a patient, and may possess medical cannabis for the caregiver’s personal use.

Registered designated caregivers are subject to a criminal background check. If the caregiver has a disqualifying felony offense, the commissioner is prohibited from registering that caregiver. Registered designated caregivers are also subject to criminal sanctions for diversion of medical cannabis in the same way as patients. (For more information on that criminal sanction, see page 12).

**Parents, legal guardians, and spouses**

A parent, legal guardian, or spouse, if listed on the registry verification as a patient’s caregiver, may act as a patient’s caregiver without having to register as a designated caregiver. Parents,

---

18 Minn. Stat. § 152.30.
19 Minn. Stat. § 152.27, subd. 4.
20 Disqualifying felony offenses are defined as violations of any state or federal controlled substance law that would be a felony in Minnesota, regardless of the sentence imposed, unless the commissioner determines that the conviction was for either the use or assistance with use of medical cannabis. Minn. Stat. § 152.22, subd. 3.
21 Minn. Stat. § 152.27, subd. 5.
legal guardians, and spouses are also subject to criminal sanctions for diversion of medical cannabis in the same way as patients. (For more information on that criminal sanction, see page 12).

**Civil and criminal protections**

**Presumption.** Once a patient enrolls in the registry program, there is a presumption that the patient is engaging in the authorized use of medical cannabis. This presumption may be rebutted by evidence that the patient’s use of medical cannabis was not for the purpose of treating the patient’s qualifying medical condition or associated symptoms.

**Exemption from criminal sanctions for use or possession.** Patients who use or possess medical cannabis, registered designated caregivers who possess medical cannabis, and, if listed on the registry verification, parents, legal guardians, and spouses who possess medical cannabis, are exempt from criminal sanctions for use or possession of a controlled substance.

**Forfeiture.** Medical cannabis and associated property are not subject to forfeiture under Minnesota law.

**Search warrant needed to access registry.** Law enforcement personnel must have a valid search warrant to access the patient registry.

**Use of registry verification or application to support a search.** A person’s possession of a registry verification or registry program application does not constitute probable cause or reasonable suspicion, and cannot be used to support a search of the person or property.

**Circumstances in which penalties still apply.** Although a patient is exempt from criminal sanctions for possession under Minnesota law, the patient is not exempt from penalties for:

1) undertaking any task under the influence of medical cannabis that would constitute negligence or professional malpractice;

2) possessing or using medical cannabis:
   i) on a school bus or van;
   ii) on the grounds of any preschool, primary school, or secondary school;
   iii) in any correctional facility; or
   iv) on the grounds of any child care facility or home daycare;

3) vaporizing medical cannabis:
   i) on any form of public transportation;
   ii) where the vapor may be inhaled by a nonpatient minor child; or

---

22 *See generally Minn. Stat. § 152.32, subds. 1, 2.*
iii) in a public place, including any indoor or outdoor area used by or open to the general public or a place of employment; and

4) operating, navigating, or being in actual physical control of any motor vehicle, aircraft, train, or motorboat, or working on transportation property, equipment, or facilities while under the influence of medical cannabis.

Criminal sanctions

Diversion of medical cannabis. A patient, registered designated caregiver, or, if listed on the registry verification, a parent, legal guardian, or spouse of a patient who intentionally sells or otherwise transfers medical cannabis to a person other than a patient, registered designated caregiver, or, if listed on the registry verification, a parent, legal guardian, or spouse, is guilty of a felony. This crime is punishable by imprisonment for not more than two years or payment of a fine of not more than $3,000, or both.

False statements. A person who intentionally makes a false statement to law enforcement about any fact or circumstance relating to the use of medical cannabis in order to avoid arrest or prosecution is guilty of a misdemeanor. This crime is punishable by imprisonment for up to 90 days, payment of a fine of not more than $1,000, or both, in addition to any other applicable penalty under the law. A patient or a registered designated caregiver convicted of this crime is disqualified from any further participation in the registry program.

Patient discrimination prohibited

A patient is protected from discrimination in a variety of circumstances.

Enrollment in school. A school cannot refuse to enroll a person or otherwise penalize a person solely because the person is enrolled in the medical cannabis registry program. This prohibition does not apply if enrolling the person would cause the school to violate federal law or cause the school to lose a monetary or licensing-related benefit under federal law.

Leasing. A landlord cannot refuse to lease to a person or otherwise penalize a person solely because the person is enrolled in the medical cannabis registry program. This prohibition does not apply if leasing to the person would cause the landlord to violate federal law or cause the landlord to lose a monetary or licensing-related benefit under federal law.

Medical care. A patient’s use of medical cannabis under the registry program is considered the authorized use of medication for purposes of medical care, including organ transplants. This use

---

23 See Minn. Stat. § 144.413, subd. 1b, for a definition of place of employment.
24 Minn. Stat. § 152.23.
25 See generally Minn. Stat. § 152.33, subd. 2.
26 Minn. Stat. § 152.33, subd. 3.
27 Minn. Stat. § 152.32, subd. 3.
of medical cannabis is not the use of an illicit substance and does not disqualify a patient from needed medical care.

**Employment.** An employer is prohibited from discriminating against a person in hiring, termination, or any term or condition of employment, or otherwise penalize the employee based on:

- the person’s status as a patient in the registry program; or
- a patient’s positive drug test for cannabis components or metabolites, unless the patient used, possessed, or was impaired by medical cannabis while on the employer’s premises or during the hours of employment.

An employer is not required to take actions, however, that would violate federal law or cause the employer to lose a federal monetary or licensing-related benefit. If an employee is required to take a drug test for the employer pursuant to section 181.953, the employee may present verification of enrollment in the patient registry as part of the employee’s explanation of a positive urine test under section 181.953, subdivision 6.

**Custody/Visitation.** A person cannot be denied custody of a minor child or visitation rights with a minor child solely based on a person’s status as a patient enrolled in the registry program. The law also provides that there is no presumption of neglect or child endangerment for conduct allowed under the registry program, unless the person’s behavior creates an unreasonable danger to the safety of the child as established by clear and convincing evidence.

**Federally approved clinical trials**

The Commissioner of Health must provide information to all patients about the existence of any federally approved clinical trials for the treatment of that patient’s qualifying medical condition with medical cannabis. The commissioner may prohibit enrollment of a patient in the registry program if that patient is simultaneously enrolled in a federally approved clinical trial for the treatment of the patient’s qualifying condition with medical cannabis.

**Manufacturers**

**Regulation Fees**

The Commissioner of Health collects from manufacturers an annual fee for the cost incurred by MDH for the regulation and inspection of the manufacturer for that year. The yearly fee amount is established by the Commissioner of Health. Each manufacturer is allowed to charge patients enrolled in the program a “reasonable fee” for operating costs of the manufacturer. Manufacturers are allowed, but not required, to establish a sliding scale of patient fees based

---

29 Minn. Stat. § 152.35.
on a patient’s household income. Manufacturers may also accept private donations in order to reduce patient fees.

Operating documents

A manufacturer’s operating documents must include procedures for oversight, procedures to ensure accurate recordkeeping, procedures for appropriate security measures to deter theft and unauthorized entrance into areas that contain medical cannabis, and procedures for the delivery and transportation of hemp between hemp growers and manufacturers.

Location and number of facilities

Each manufacturer is required to have eight distribution facilities and one production facility (the production facility may be at the same location as a distribution facility). The requirement to operate eight distribution facilities became effective in July 2019; before that date, each manufacturer was required to operate four distribution facilities.

The commissioner must designate geographic service areas served by each manufacturer, and a manufacturer cannot have more than two distribution facilities in each assigned service area. No facility may be within 1,000 feet of a public or private school that was in existence prior to the manufacturer’s registration with MDH. As of October 2019, distribution facilities are located in Bloomington, Eagan, Hibbing, Minneapolis, Moorhead, Rochester, St. Cloud, and St. Paul. As of December 2019, Leafline Labs proposes establishing additional distribution facilities in Willmar, Mankato, Golden Valley, and Rogers, and Minnesota Medical Solutions proposes to establish additional facilities in Woodbury, Blaine, Duluth, and Burnsville.

Employees

A manufacturer is prohibited from employing any person under the age of 21 or any person who has been convicted of a disqualifying felony offense. However, a manufacturer may employ a person who has been convicted of a disqualifying felony offense if the Commissioner of Health determines the conviction was for the use of or assistance with the use of medical cannabis. All potential employees must undergo a criminal history background check through the Bureau of Criminal Apprehension prior to working for the manufacturer.

Due to distribution requirements, manufacturers must also employ at least one pharmacist licensed in Minnesota. The pharmacist employees must be the only employees who give final

30 Minn. Stat. § 152.29, subd. 1, para. (d).
31 Minn. Stat. § 152.29, subd. 1, paras. (a) and (k).
32 Minn. Stat. § 152.29, subd. 1, para. (j).
33 A disqualifying felony offense is defined as a violation of any state or federal controlled substance crime that would be a felony under Minnesota law, whether or not the offense was committed in Minnesota and regardless of the sentence imposed. Minn. Stat. § 152.22, subd. 3.
approval for distribution of medical cannabis and must consult with the patient before distributing the medical cannabis.\textsuperscript{34}

Any employee of the manufacturer involved in delivering medical cannabis or medical cannabis products from one location to another or to the other manufacturer must carry identification showing that the person is an employee of the manufacturer.\textsuperscript{35}

\textbf{Security}\textsuperscript{36}

Manufacturers must have certain security measures at all distribution sites as well as the production site. These security measures must include:

- procedures for the delivery and transportation of hemp between hemp growers and manufacturers;
- a fully operational security alarm system;
- facility access controls;
- perimeter intrusion detection systems; and
- a personnel identification system.

\textbf{Testing medical cannabis for content, contamination, consistency}\textsuperscript{37}

Each manufacturer must contract with an independent laboratory approved by the Commissioner of Health to test the manufacturer’s medical cannabis and hemp acquired by the manufacturer for content, contamination, and consistency. The cost of this contract must be paid by the manufacturer and is subject to any additional requirements set by the Commissioner of Health. The commissioner developed stock solution/final product acceptance criteria for use when testing medical cannabis and hemp, specifying maximum allowed levels for metals, toxins, microbials, and solvents, and testing requirements for pesticides.\textsuperscript{38}

\textbf{Inspections}\textsuperscript{39}

Manufacturers are subject to reasonable inspections by the Commissioner of Health. Each manufacturer must keep detailed financial records in a manner approved by the commissioner and make these records available for the commissioner’s review. In addition, the manufacturers must submit to the commissioner the results of an annual financial audit conducted by an independent certified public accountant, paid for by the manufacturer. The commissioner may

\textsuperscript{34} Minn. Stat. § 152.29, subd. 3, paras. (a) and (c).
\textsuperscript{35} Minn. Stat. § 152.29, subd. 3, para. (d).
\textsuperscript{36} Minn. Stat. § 152.29, subd. 1, para. (e).
\textsuperscript{37} Minn. Stat. § 152.29, subd. 1, para. (c).
\textsuperscript{38} These acceptance criteria are found at https://www.health.state.mn.us/people/cannabis/docs/safety/mnmacccriteria.pdf.
\textsuperscript{39} Minn. Stat. §§ 152.29, subd. 1, para. (h); 152.37.
require a second financial audit by a certified public accountant chosen by the commissioner, also at the expense of the manufacturer.

The commissioner or the commissioner’s designee may examine the business affairs of the manufacturer, including a review of the manufacturer’s financing, budgets, revenues, sales, and pricing. The commissioner may retain outside professionals, such as attorneys and certified public accountants, to conduct or assist with this examination, but may not retain the same certified public accountant as used in the annual audit. If the commissioner conducts this examination, the commissioner must complete a report and provide a copy to the manufacturer and post a copy on the department’s website. All data collected during this examination, except for the public report, are private data on individuals or nonpublic data.

**Monthly report to commissioner**

Each manufacturer must submit a monthly report to the Commissioner of Health. The report must include the following information for each patient served in the prior month:

- the amount and dosages of medical cannabis distributed
- the chemical composition of the medical cannabis
- the tracking number assigned to any medical cannabis distributed

These reports are not public. MDH compares data in the reports to data in the medical cannabis registry to ensure that the medical cannabis registry has a record of all medical cannabis transactions. MDH has also used these reports to fill in incomplete records in the registry.

**Distribution**

**What may be distributed**

A manufacturer may only distribute medical cannabis as a pill, liquid, or topical formulation. In December 2019 the Commissioner of Health added the following delivery methods: water-soluble cannabinoid multi-particulates (including things like granules, powder, and sprinkles) and orally dissolvable products (such as lozenges, gum, mints, buccal tablets, and sublingual tablets). These delivery methods will be available at distribution facilities beginning August 1, 2020. Manufacturers are allowed, but not required, to distribute medical cannabis products, such as delivery devices and educational material.

All medical cannabis must be assigned a tracking number and be packaged in compliance with the United States Poison Prevention Packaging Act. All medical cannabis must also be labeled with the following information:

---

40 Minn. Stat. § 152.29, subd. 4.

41 Minn. Stat. §§ 152.22, subd. 6; 152.29, subd. 3.

42 15 U.S.C. §§ 1471-1477. (The United States Poison Prevention Packaging Act, P.L. 91-601, was enacted to protect children from unintended ingestion of medicines and common household products.)
- All active ingredients
- Individually identifying information, including:
  - the patient’s name and date of birth
  - if applicable, the name and date of birth of the patient’s registered
designated caregiver or parent or legal guardian
  - the patient’s registry identification number
  - the chemical composition
  - the dosage

**People allowed to receive medical cannabis**\(^{43}\)

A manufacturer may distribute medical cannabis only to a person listed on the patient’s registry
verification that the manufacturer received from MDH. The manufacturer may not distribute
any medical cannabis until the registry verification has been received. The registry verification
includes patient information and may also include a registered designated caregiver or a
parent, guardian, or spouse of the patient. If a person is listed on the registry verification, the
manufacturer may distribute the medical cannabis after verifying the person’s identity by
photographic identification, unless the individual distributing the medical cannabis personally
knows the recipient.\(^{44}\)

**Who may distribute the medical cannabis**\(^{45}\)

Only employees of the manufacturer who are licensed pharmacists in Minnesota may give final
approval for distribution of medical cannabis. Distribution may only occur after a pharmacist
has consulted with the patient to determine the proper dosage and range of chemical
compositions for that individual patient. The pharmacist may consult with the patient via
videoconference, as long as the consultation meets certain requirements.

**Amount of medical cannabis that can be distributed**\(^{46}\)

A maximum of a 90-day supply of the dosage determined for the individual patient may be
distributed at one time.

\(^{43}\) Minn. Stat. § 152.29, subd. 3.

\(^{44}\) Minn. Stat. § 152.11, subd. 2d.

\(^{45}\) Minn. Stat. § 152.29, subd. 3, para. (a).

\(^{46}\) Minn. Stat. § 152.29, subd. 3, para. (c), cl. (6).
Other

Relationship with health care practitioners\textsuperscript{47}

A manufacturer must not share office space with a health care practitioner. A manufacturer is also prohibited from referring patients to a health care practitioner or having any financial relationship with a health care practitioner.

Marketing restrictions\textsuperscript{48}

Manufacturers must comply with reasonable restrictions set by the Commissioner of Health relating to signage, marketing, display, and advertising of medical cannabis.

Transportation\textsuperscript{49}

A manufacturer may staff a motor vehicle with one employee to transport medical cannabis to a certified laboratory to be tested or to a facility for disposal or to transport hemp for any purpose. A manufacturer must staff a motor vehicle with at least two employees when transporting medical cannabis for any other purpose or to any other destination.

Criminal and civil liability\textsuperscript{50}

The law establishes criminal penalties that apply to manufacturers or employees of manufacturers in addition to any other applicable penalty in law. Any manufacturer or agent of a manufacturer who intentionally transfers medical cannabis to a person other than one listed on a registry verification or another registered manufacturer, or who submits false records or documentation required by MDH to register as a manufacturer is guilty of a felony punishable by up to two years of imprisonment, a fine of not more than $3,000, or both. If certain individuals affiliated with a manufacturer intentionally divert medical cannabis outside the state to a person other than allowed by law, the commissioner may fine the manufacturer $250,000 and may begin proceedings to revoke the manufacturer’s registration. A manufacturer may also be fined up to $1,000, in addition to any other applicable penalty in law, for any violation of laws or regulations relating to the registry program where no penalty is specified.

Criminal protections\textsuperscript{51}

Employees of a manufacturer or an independent laboratory that tests medical cannabis are exempted from criminal liability under Minnesota law for the possession, dosage determination, and sale of medical cannabis as permitted under the registry program.

\textsuperscript{47} Minn. Stat. § 152.29, subd. 1, para. (f).
\textsuperscript{48} Minn. Stat. § 152.29, subd. 1, para. (l).
\textsuperscript{49} Minn. Stat. § 152.29, subd. 3a.
\textsuperscript{50} Minn. Stat. § 152.33, subs. 1, 4, and 6.
\textsuperscript{51} Minn. Stat. § 152.32, subd. 2.
Data practices

Data submitted to a medical cannabis manufacturer, and data submitted by a medical cannabis manufacturer to the Commissioner of Health, are classified as private data on individuals or nonpublic data. This data may be used to comply with requirements in chapter 13 and to comply with requests from the legislative auditor or state auditor.

Health Care Practitioners

A health care practitioner, for purposes of the registry program, is defined as a Minnesota-licensed doctor of medicine, a Minnesota-licensed physician assistant acting within the scope of practice, or a Minnesota-licensed advanced practice registered nurse, with the primary responsibility for care and treatment of the patient’s underlying qualifying medical condition.

Participation

MDH training/notification

The Commissioner of Health must notify all eligible health care practitioners in the state about the registry program. This notice must include an explanation of the purposes and requirements of the program. If a health care practitioner meets the requirements and requests to participate in the program, the commissioner must allow that participation. However, no health care practitioner is required to participate in the program. In addition to notification, the commissioner also must provide practitioners with explanatory information and assistance in understanding the therapeutic uses of medical cannabis under the program requirements. The commissioner must provide patient applications to participating health care practitioners, who then provide those applications to patients.

Certifications

In order for a patient to participate in the registry program, a health care practitioner must provide the patient with a certification of diagnosis with at least one qualifying medical condition. The certification must have been given by the practitioner within the 90 days prior to the patient’s application. Practitioners must use the certification form developed by the Commissioner of Health.

In certain circumstances, the practitioner may also provide a certification of a patient’s disability as part of the patient’s certification of diagnosis. The law allows for patients in the registry program to have a registered designated caregiver if the patient requires assistance.

52 Minn. Stat. § 152.31.
53 Minn. Stat. § 152.22, subd. 4.
54 Minn. Stat. § 152.27, subd. 2, para. (a).
55 Minn. Stat. § 152.28, subd. 1, para. (d).
56 Minn. Stat. § 152.28, subd. 1, para. (a), cls. (1) and (2).
with administering medical cannabis or obtaining medical cannabis from a distribution facility due to a developmental or physical disability.

**Responsibilities during participation**\(^{57}\)

If a health care practitioner agrees to participate in the registry program, the practitioner must continue to treat the patient for the patient’s qualifying medical condition. Throughout that ongoing treatment, the practitioner must report the health records of the patient to the commissioner. The reporting of health records must be made in a manner set by the commissioner and is subject to data privacy provisions. Each year, the practitioner also must determine if the patient continues to suffer from a qualifying medical condition and, if so, issue a new certification of that diagnosis. A patient assessment for recertification may be conducted via telemedicine.

**Advice to patients and others**\(^{58}\)

A health care practitioner working with a patient in the program must provide the patient, registered designated caregiver, and parent, legal guardian, or spouse with information on nonprofit patient support groups or organizations. The practitioner is also required to provide explanatory information provided by MDH disclosing:

- the experimental nature of therapeutic use of medical cannabis;
- the possible risks, benefits, and side effects of the proposed treatment;
- the application for participation in the program;
- other materials from the commissioner; and
- the Tennessen warning.\(^{59}\)

**Medical Assistance/MinnesotaCare reimbursement**\(^{60}\)

Medical Assistance (MA) and MinnesotaCare are not required to reimburse an enrollee or a provider for “costs associated with the medical use of cannabis.” Medical cannabis is not listed on the drug formulary for MA and MinnesotaCare, so those programs do not cover medical cannabis.\(^{61}\) MA and MinnesotaCare are, however, still required to reimburse for services related to the treatment of the patient’s qualifying medical condition if that service is covered under applicable statutes.

---

\(^{57}\) Minn. Stat. § 152.28, subd. 1, paras. (a), cl. (5), (b), and (c).

\(^{58}\) Minn. Stat. § 152.28, subd. 1, para. (a), cl. (3) and (4).

\(^{59}\) See Minn. Stat. § 13.04, subd. 2 (explaining the Tennessen warning).

\(^{60}\) Minn. Stat. § 152.23, para. (b).

\(^{61}\) See Minn. Stat. § 256B.0625, subd. 13d; Minnesota Health Care Programs Provider Manual, http://www.dhs.state.mn.us.
Legal Issues

Health records

All data collected on patients and reported to the patient registry are health records under the Health Records Act and are classified as private data on individuals. The data may, however, be used or reported in an aggregated, nonidentifiable form as part of the scientific, peer-reviewed publication of research required under the law or in the creation of summary data.

Civil/disciplinary protections

The law prohibits the Board of Medical Practice, the Board of Nursing, or any other professional licensing board from subjecting a health care practitioner to any civil or disciplinary penalties solely for participation in the registry program. This protection also extends to pharmacists under the Board of Pharmacy. The protection does not prevent a professional licensing board from taking action in response to violations of any other section of law. The law also does not provide any civil protections for health care practitioners for claims of malpractice, negligence, or any other civil claim.

Criminal liability

Although the law creates exemptions from criminal liability for certain actions by patients, caregivers, and manufacturers, it does not exempt health care practitioners from criminal liability. Under the registry program, a health care practitioner does not possess or distribute medical cannabis and is therefore not exempted from criminal controlled substance possession laws.

A health care practitioner is subject to a misdemeanor penalty, punishable by up to 90 days in jail or payment of a fine up to $1,000, or both, for the following actions:

- knowingly providing patients with referrals to a specific manufacturer or a specific designated caregiver
- advertising as a manufacturer
- issuing a certification that a patient has a qualifying medical condition while holding a financial interest in a manufacturer

A case decided by the federal Court of Appeals for the Ninth Circuit addressed whether a health care practitioner may be criminally liable for aiding and abetting a federal crime for the physician’s “recommendation” to a patient to use marijuana for medicinal purposes. In Conant v. Walters, the court held that a doctor’s “recommendation” alone did not amount to aiding and abetting. The case was based on California law that required a doctor to “recommend” a

---

62 Minn. Stat. §§ 152.28, subd. 2; 152.31.
63 Minn. Stat. § 152.32, subd. 2, para. (c).
64 Minn. Stat. § 152.33, subd. 5.
65 Conant v. Walters, 309 F.3d 629 (9th Cir. 2002).
patient’s use of medical marijuana. Minnesota law differs from California law in that respect, as a practitioner in Minnesota is providing a “certification of diagnosis” and not a “recommendation.” It is also important to note that the Ninth Circuit Court of Appeals does not have jurisdiction over Minnesota and therefore this decision is not binding on Minnesota courts.

**Advertising restrictions**

Health care practitioners are prohibited from publishing advertisements that:

- contain false or misleading statements about medical cannabis or the registry program;
- use colloquial terms to refer to medical cannabis;
- state or imply that a health care practitioner is endorsed by MDH;
- include images of cannabis or of cannabis-smoking paraphernalia; or
- contain medical symbols that may be confused with symbols of medical associations.

A health care practitioner who violates these advertising restrictions cannot certify patients to participate in the registry.

**Other**

**Prescription Monitoring Program**

Medical cannabis is not eligible to be entered into the Prescription Monitoring Program (PMP). Under Minnesota and federal law, cannabis is a Schedule I controlled substance, and therefore medical cannabis is not dispensed under a prescription drug order, as required by statute to be entered in the PMP.

**Discrimination for purposes of medical care prohibited**

Discrimination against patients for the purpose of medical care is prohibited. The law states that a patient’s use of medical cannabis is considered equivalent to the authorized use of any other medication and does not constitute the use of an illicit substance or otherwise disqualify a patient from needed medical care, including organ transplants.

---

66 Minn. Stat. § 152.28, subd. 3
67 Minn. Stat. § 152.126.
68 The Prescription Monitoring Program (PMP) is codified in Minnesota Statutes, section 152.126. The PMP allows health care practitioners with prescribing authority to check the database for a patient’s history of controlled substance prescriptions. The information in the PMP is generally inputted by the pharmacist who delivers the controlled substance. Among the included substances in the PMP are all substances classified as a Schedule II through V.
69 Minn. Stat. § 152.32, subd. 3, para. (b).
Health care facilities and home care providers

Under the law, health care facilities and home care providers may adopt reasonable restrictions on the use of medical cannabis by a patient who resides at or is actively seeking care or treatment at the facility or from the provider. For purposes of this provision, health care facilities include those licensed under chapter 144A (nursing homes and hospice facilities), boarding care homes and supervised living facilities licensed under section 144.50, assisted living facilities, facilities owned, controlled, managed, or under common control with hospitals licensed under chapter 144, and other health facilities licensed by the commissioner of health. Restrictions may include that the facility or provider will not store or maintain the patient’s medical cannabis supply, that the facility or provider is not responsible for providing the medical cannabis for patients, and that medical cannabis may only be used in specified places within the facility. The facilities and providers are not required to adopt any restrictions and are prohibited from unreasonably limiting a patient’s access to or use of medical cannabis.

Employees of a health care facility, emergency medical services personnel, and home care providers are not subject to a violation under this chapter for possessing medical cannabis during the course of their duties and may distribute medical cannabis to a registered patient who resides at or is seeking active care and treatment at the facility or from the provider. Under this section, employees acting within the course of their duties are not required to register as a designated caregiver.

Operation of the Program

Appropriations

MDH receives appropriations from the general fund and the state government special revenue fund to fund the activities of its Office of Medical Cannabis. Appropriations from the state government special revenue fund are from annual registration fees collected from manufacturers and annual fees collected from patients for enrollment in the patient registry.

<table>
<thead>
<tr>
<th>Appropriations to MDH for the Office of Medical Cannabis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiscal Year</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>FY 2015</td>
</tr>
<tr>
<td>FY 2016</td>
</tr>
<tr>
<td>FY 2017</td>
</tr>
<tr>
<td>FY 2018</td>
</tr>
<tr>
<td>FY 2019</td>
</tr>
</tbody>
</table>

70 Minn. Stat. §§ 144A.4791, subd. 14; 152.34.
<table>
<thead>
<tr>
<th>Appropriations by Fund</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2020</td>
<td>$771,000</td>
<td>$2,116,000</td>
</tr>
<tr>
<td>FY 2021</td>
<td>$779,000</td>
<td>$1,984,000</td>
</tr>
</tbody>
</table>

**Task Force on Medical Cannabis Therapeutic Research**\(^{71}\)

The Task Force on Medical Cannabis Therapeutic Research was established to conduct an impact assessment of the registry program on Minnesota. Initially the task force was also involved in certain deadline extensions for the program. The 23-member task force consists of representatives from:

- the House of Representatives and the Senate;
- consumers or patients enrolled in the registry program;
- health care providers;
- law enforcement and prosecutors;
- substance use disorder treatment providers; and
- the commissioners of health, human services, and public safety.

All members, except the members from the House of Representatives and the Senate, are appointed by the governor. Two members of the House of Representatives and two members of the Senate are also appointed, with one member of each body serving as a co-chair. The co-chairs are appointed by the Senate majority leader and the Speaker of the House. The second member from each body is appointed by the minority leader of that body. All members serve at the pleasure of their appointing authority. The Commissioner of Health provides administrative and technical support to the task force.

**Deadline extensions**\(^{72}\)

The task force could have extended the deadline to register manufacturers and the distribution deadline by six months if requested by the Commissioner of Health. MDH did register two manufacturers by the December 1, 2014, deadline, and the manufacturers began distributing medical cannabis on the July 1, 2015, deadline, so no extensions were needed.

**Cost assessments**

Beginning with a report on January 15, 2015, and continuing annually until January 15, 2019, the commissioners of the state executive agencies impacted by the medical cannabis therapeutic research study were required to report to the co-chairs of the task force the costs

---

\(^{71}\) Minn. Stat. § 152.36.

\(^{72}\) Minn. Stat. § 152.25, subd. 3.
incurred by each agency in implementing the study. Agencies were required to report actual costs incurred compared to estimated costs.

Impact assessments

The task force must complete an impact assessment and report it to the legislature every two years beginning in 2017. The impact assessment must be conducted by holding hearings to evaluate the impact of medical cannabis and hemp use and evaluate Minnesota’s activities involving medical cannabis and hemp. The impact assessment must include analysis of:

- the program design and implementation;
- the impact on the health care provider community;
- patient experiences;
- the impact on the incidence of substance abuse;
- access to and quality of medical cannabis, hemp, and medical cannabis products;
- the impact on law enforcement and prosecutions;
- public awareness and perception; and
- any unintended consequences.

The task force issued its first impact assessment report February 1, 2017.73 In that report, the task force provided an overview of Minnesota’s medical cannabis program’s design and implementation; participation in the program by patients, health care practitioners, and registered designated caregivers; and rules adopted by the department. The report also described the department’s periodic surveys of patients and health care practitioners regarding benefits and negative effects of medical cannabis use and included survey results for the July to September 2015 time period. No substance abuse impacts related to the medical cannabis program or serious adverse incidents related to overdoses or diversions have been reported to the department. Additionally, the report summarized testing requirements for medical cannabis and factors that affect access to medical cannabis. Finally, the report provided information about patient perceptions of the extent to which medical cannabis products for sale in Minnesota meet patient needs.

Additional reports to the legislature

The task force had to report to the legislature by February 1, 2015, on the design and implementation of the registry program. In addition, it must make reports based on the biennial cost assessments from the state agencies.

At any time, the task force may recommend to the legislature whether to add or remove conditions from the list of qualifying medical conditions.

73 This report may be found on the Minnesota Department of Health’s website at http://www.health.state.mn.us/people/cannabis/docs/taskforce/reportfinal061417.pdf
Legislative History of Medical Cannabis Regulation in Minnesota

1980. In 1980, the THC Therapeutic Research Act was adopted and signed into law. The purpose of the act was to research whether cannabis could alleviate the effects of chemotherapy during the treatment of cancer. The act required the Commissioner of the Department of Health to appoint a principal investigator. The principal investigator was required to obtain cannabis only from the National Institute on Drug Abuse and comply with federal laws and regulations while conducting the research program. In 1980, $100,000 was appropriated by the legislature to the Commissioner of Health to administer the act, but the appropriation was vetoed by Governor Al Quie.

2001. In 2001, Representative Phyllis Kahn introduced House File 2164, known as the Compassionate Use Act. That act would have allowed for the medical use of cannabis after a patient had been diagnosed by a physician as having a debilitating medical condition. The House bill, and its companion bill in the Senate, were both introduced but not heard in committee.

2007. In 2007, Representative Thomas Huntley introduced House File 655 and Senator Steve Murphy introduced Senate File 345. Both bills would have allowed the use of medical cannabis for treatment of a debilitating medical condition. The Senate file passed the Senate floor and was referred to the House where it was given a second reading, but not passed.

2009. In 2009, the first medical cannabis law that would have allowed patient possession of medical cannabis passed both bodies of the legislature. The act allowed patients to possess and use cannabis if diagnosed with a terminal illness that was accompanied by a variety of symptoms. The act passed both the House and the Senate and was vetoed by Governor Tim Pawlenty on May 22, 2009.

2013. In 2013, Representative Carly Melin and Senator Scott Dibble introduced House File 1818 and Senate File 1641, respectively, both allowing for the use and possession of medical cannabis by patients with a specified list of conditions. House File 1818 was referred to committee but did not pass the House floor. Senate File 1641 passed the Senate on May 6, 2014, and was referred to the House for consideration, but was not heard in committee.

2014. On April 24, 2014, Senate File 2470, originally a bill relating to education, passed the Senate and was referred to the House for consideration. The bill was heard in the Rules and Administration Committee where an amendment was offered and adopted that allowed for the

---

74 Minn. Stat. § 152.21, subd. 1.
75 Minn. Stat. § 152.21, subd. 4.
76 Minn. Stat. § 152.21, subd. 5.
78 Laws 2009, ch. 166; Senate File 97, House File 292.
medical use of cannabis through a clinical trial model. The bill was then heard in the Ways and Means Committee where another amendment was offered and adopted, altering the program to a registry program. The bill was sent to the House floor where it was passed with additional amendments. Because the bill originated in the Senate and already passed the Senate, the Senate was able to either concur on the bill as amended or refuse to concur. The Senate refused to concur and the bill was heard in conference committee and passed by both bodies as amended in conference committee. Governor Mark Dayton signed the bill into law on May 29, 2014.79

2015. **Laws 2015, chapter 74**, amended various sections of the medical cannabis act by:

- modifying the definition of medical cannabis to include possession by a manufacturer or laboratory of any part of the cannabis plant prior to processing the plant into an approved liquid or pill form;
- establishing time limits for the Commissioner of Health to either approve or deny a patient’s application for the registry program; and
- adding facilities owned, controlled, managed, or under common control of a hospital to those facilities that may adopt reasonable restrictions on the use of medical cannabis by patients who reside at or are actively receiving care or treatment at the facility.

A provision was also added to allow employees of a health care facility, in the course of their duties, to possess medical cannabis for a registered patient without registering with the commissioner as a designated caregiver.

2016. **Laws 2016, chapter 179**, amended various sections of the medical cannabis act by:

- expanding the definition of qualifying medical condition to include inflammatory bowel disease;
- requiring the Commissioner of Health to regularly update legislators about certain topics;
- specifying that only manufacturer employees licensed as pharmacists may give final approval for distribution of medical cannabis;
- allowing patient consultations via videoconference to determine dosages;
- allowing the transportation of medical cannabis by only one manufacturer employee in certain circumstances; and
- directing the Commissioner of Health to provide administrative and technical support to the Task Force on Medical Cannabis Therapeutic Research.

A separate provision was added to statutes governing home care providers, allowing home care providers to adopt reasonable restrictions on the use of medical cannabis by patients in the registry program who receive care from home care providers, and to protect home care

---

79 **Laws 2014, ch. 311**.
provider employees from being subject to violations of controlled substance laws for carrying out employment duties and caring for patients in the registry program.

**2017. Laws 2017, first special session, chapter 6**, modified the Commissioner of Health’s authority and tools for regulating registered medical cannabis manufacturers and health care practitioners. Regarding manufacturers, the commissioner is authorized to:

- accept additional registration applications from manufacturers if a manufacturer registered before December 1, 2014, ceases to be registered;
- not renew a manufacturer’s registration, if an officer, director, or controlling person of a manufacturer diverts medical cannabis to a person other than allowed by law; and
- impose a civil penalty and revoke a manufacturer’s registration, if an officer, director, or controlling person of a manufacturer diverts medical cannabis to a person other than allowed by law and transports medical cannabis outside the state.

The law also established procedures for the commissioner to follow to revoke, not renew, deny consent to transfer, or temporarily suspend a registration of a medical cannabis manufacturer. In addition, the law prohibited health care practitioners from including certain terms, images, and symbols in their advertising. A health care practitioner who violates these advertising restrictions cannot certify patients as having qualifying medical conditions, for purposes of participating in the medical cannabis registry.

**2019. Laws 2019, first special session, chapter 9** included numerous changes to the medical cannabis act and related statutes.

- The commissioner is authorized to establish the geographic areas to be served by each manufacturer, and to use the tools and authority in the Health Enforcement Consolidation Act to enforce the medical cannabis act.

- Changes for patients and caregivers include lowering the minimum age for registered designated caregivers from 21 to 18, requiring registered designated caregivers to renew their criminal background checks every two years, allowing a spouse of a patient to act as a patient caregiver without registering as a designated caregiver, no longer listing a patient’s qualifying medical condition on the patient’s registry verification, and allowing a registered designated caregiver to also be a patient enrolled in the registry.

- Changes for manufacturers include increasing the number of distribution facilities operated by each manufacturer from four to eight, increasing the amount of medical cannabis a manufacturer may distribute to a patient from a 30-day supply to a 90-day supply, making a manufacturer registration nontransferable, allowing a manufacturer to obtain hemp from hemp growers and process hemp into an allowable form of medical cannabis, and allowing a manufacturer to transfer medical cannabis and medical cannabis products to the other manufacturer for distribution.
**Changes to Qualifying Medical Conditions and Delivery Methods**

The following table provides information on changes made to the program’s list of qualifying medical conditions and allowable delivery methods and the year in which each change went into effect. To date, all of these changes were made by the commissioner of health using the commissioner’s authority under Minnesota Statutes, section 152.27, subdivision 2, paragraph (b).

<table>
<thead>
<tr>
<th>Year Effective</th>
<th>Change to Qualifying Medical Conditions and Allowable Delivery Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>Addition of intractable pain as qualifying medical condition</td>
</tr>
<tr>
<td>2017</td>
<td>Addition of post-traumatic stress disorder (PTSD) as qualifying medical condition</td>
</tr>
<tr>
<td></td>
<td>Addition of topical formulations (patches, lotions, creams, gels, and ointments) as allowable delivery method</td>
</tr>
<tr>
<td>2018</td>
<td>Addition of autism spectrum disorder and obstructive sleep apnea as qualifying medical conditions</td>
</tr>
<tr>
<td>2019</td>
<td>Addition of Alzheimer’s disease as qualifying medical condition</td>
</tr>
<tr>
<td>2020</td>
<td>Addition of chronic pain and age-related macular degeneration as qualifying medical conditions</td>
</tr>
<tr>
<td></td>
<td>Addition of water-soluble cannabinoid multi-particulates (granules, powders, and sprinkles) and orally dissolvable products (lozenges, gum, mints, buccal tablets, and sublingual tablets) as allowable delivery methods</td>
</tr>
</tbody>
</table>